I hope you have been enjoying receiving your copies of IBD Research Review, and I am delighted to provide the expert commentary for this issue. I have included research on a range of topics, beginning with a meta-analysis of studies reporting the prevalence and incidence of, and risk factors for, neoplasia in patients with IBD following colectomy. There are two papers focussing on pregnancy, one looking at anti-TNF drug exposure and clearance in neonates born to mothers receiving these agents, and the other reporting birth outcomes for women with IBD who have received assisted reproductive therapies. The last paper reports an association between higher adalimumab concentrations and mucosal healing in patients with CD. I am keen to hear your thoughts on these papers and other research in IBD, so feel free to contact me at the email address below. Kind Regards, Dr Edward Shelton, MBBS (Hons.), FRACP edward.shelton@researchreview.com.au
Risk of neoplasia after colectomy in patients with inflammatory bowel disease
Authors: Derikx LAAP et al. Summary: This systematic review and meta-analysis reported CRC (colorectal cancer) prevalences from patients who underwent rectal stump surgery (13 studies), IRA (ileorectal anastomosis; 35 studies) or IPAA (ileal pouch anal anastomosis; 33 studies). Compared with the IPAA group, significantly greater proportions of patients in the rectal stump and IRA groups developed CRC (2.1% and 2.4%, respectively, vs. 0.5%; OR for IRA plus rectal stump versus IPAA group, 6.4 [95% CI 4.3 -9.5]). The most important risk factor for developing postcolectomy CRC was a history of CRC (respective ORs following IRA and IPAA, and 15.0 [6.6-34.5 
]).
Comment: Colonic IBD patients may undergo colectomy with restorative procedures including IPAA, IRA or permanent end ileostomy with rectal stump. There is a risk for neoplasia in the ileoanal pouch or residual rectum, but data to guide our surveillance are limited. In this systematic review, a greater proportion of patients with residual rectums (2.1% and 2.4% for rectal stump and IRA) compared with patients with IPAA (0.5%) developed neoplasia (6.4× risk). Risk factors for neoplasia following IPAA and IRA included IBD duration and prior colorectal neoplasia, with insufficient data to assess primary sclerosing cholangitis and pouchitis as risk factors. This analysis helps to inform us on the risk of cancer following colectomy, with prevalence in the pouch after IPAA being very low and around 1/10 lifetime risk of CRC in the general population (~1 in 21). These estimates will be helpful when discussing surgical options with patients and guiding surveillance, particularly in patients with a residual rectum, long duration of IBD and prior colorectal neoplasia.
Reference : Clin Gastroenterol Hepatol 2016; 14(6):798-806 Abstract CD = Crohn's disease; CRC = colorectal cancer; CTE = computed tomographic enterography; FODMAP = fermentable oligosaccharides, disaccharides, monosaccharides and polyols; GI = gastrointestinal; IBD = inflammatory bowel disease; IPAA = ileal pouch anal anastomosis; IRA = ileorectal anastomosis; MRE = magnetic resonance enterography; OR = odds ratio; SCCAI = Simple Clinical Colitis Activity Index; TNF = tumour necrosis factor; UC = ulcerative colitis. Comment: Functional GI symptoms occur in 35-57% of patients with quiescent IBD and patients commonly inquire about dietary therapy and seek nonmedical dietary recommendations via the Web. In this prospective study, patients were provided advice by a registered dietician rather than given a strict diet, which reflects real-world practice. Many of us have already extrapolated findings from non-IBD patients and utilised the low FODMAP diet in our IBD patients with functional GI symptoms. This study provides further evidence for its utility. We need to be judicious with implementation of dietary restriction in IBD to prevent unnecessary dietary restrictions. With the high proportion of IBD patients with functional GI symptoms, this study reinforces the need for objective measures of gut inflammation prior to therapy escalation.
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Reference: Inflamm Bowel Dis 2016;22(5):1129-36
Abstract
Radiological response is associated with better long-term outcomes and is a potential treatment target in patients with small bowel Crohn's disease Authors: Deepak P et al.
Summary: This paper reported on 150 patients with small-bowel CD of median 9 years duration who had undergone pretherapy CTE (CT enterography)/MRE and follow-up CTE or MRE after 6 months, or two CTE/MREs ≥6 months apart during maintenance therapy. The patients had 223 inflamed small bowel segments, including 76 with strictures and 62 with penetrating, nonperianal disease, and 49% had ileal distribution. The respective complete and partial radiological response rates were 37% and 26%, leaving 37% as nonresponders. Comment: We are increasingly adopting a treat-to-target strategy in CD to optimise patient outcomes. Mucosal healing with ileocolonoscopy is the most important target, but can be limited in assessing transmural involvement, more proximal disease and disease beyond strictures. Targets are also less clearly defined in isolated small-bowel CD. In addition, faecal calprotectin is less useful and assessment with capsule endoscopy is expensive. This study retrospectively evaluated disease progression using CTE and MRE in 150 small-bowel CD patients who had baseline imaging prior to treatment initiation with follow-up imaging on therapy (median time 451 days). Radiological response to medical therapy was associated with significant reductions in corticosteroid rescue, hospitalisation and surgery among small-bowel CD patients, suggesting the significance of radiological response as a treatment target. This offers an alternative target in patients with isolated small-bowel CD, with the aim of altering the natural history of CD. Interestingly, nearly 1 in 2 patients with a normal terminal ileum had evidence of active disease on imaging at the terminal ileum or more proximal to it. Comment: Nonadherence to therapy in IBD patients is an important consideration in assessment of our patients and in nonresponders. We can independently assess nonadherence with thiopurine metabolite testing and ensure patients receive their drug with infliximab infusions. The higher rate of nonadherence in patients taking mesalazine may be related to higher pill burden or milder disease activity. Higher education level is associated with decreased adherence similar to the trend seen with vaccination uptake. Paradoxically, taking time to educate our patients regarding disease and medication is likely to increase adherence. Comment: There are limited data to guide our management in the face of malignancy. Society guidelines generally recommend waiting 5 years prior to recommencement of immunosuppressive therapy, but this is expert opinion only. Due to the small number of events, large population-based registries are needed to detect cancer recurrence. This study used Medicare data and combined IBD and rheumatoid arthritis populations to include 2684 women with a prior history of breast cancer to detect the risk of breast cancer recurrence. Reassuringly, there was no increased risk with immunosuppressive therapy compared with no therapy. There is no comment on combination therapy, and these data do not help us to select an individual therapy over another in a patient with prior breast cancer, although it doesn't suggest that anti-TNF therapy is higher risk in this population as has been previously suggested. We are also not further informed regarding the optimal timing of therapy recommencement following a cancer diagnosis, and this needs to be a joint decision between the oncologist and IBD physician. These data are reassuring for clinicians and will help inform practice in the setting of malignancy.
Reference: Arthritis Rheumatol; Published online May 9, 2016 Abstract
Diagnostic performance of the Simple Clinical Colitis Activity Index self-administered online at home by patients with ulcerative colitis
Authors: Marín-Jiménez I et al., and on behalf of the CRONICA-UC study investigators Summary: The CRONICA-UC study followed 199 patients with UC for 6 months, during which time they completed the SCCAI (Simple Clinical Colitis Activity Index) assessment online at home at 3 months and 6 months. For reference, gastroenterologists completed the in-clinic SCCAI within 48 hours. There was good correlation between the patients' and physicians' SCCAI scores (Spearman's ρ=0.79), with 85% agreement for remission or activity (κ=0.66). Agreement between the patients and physicians was greater at 6 months than at 3 months (89.3% vs. 80.8% [p=0.027] ). The respective negative and positive predictive values for active disease were 94.5% and 68.0%.
Comment: New communication technologies including telemedicine and smartphone applications are well accepted by patients, but not commonly implemented by clinicians. The SCCAI is a simple disease assessment tool and is entirely composed of clinical items, making it useful in the clinic and also feasible for patients to remotely self-assess UC activity. The high negative predictive value for active disease means that this tool could be implemented to remotely assess patients. This could limit requirement for stable patients to attend clinic, allowing physicians in busy clinics to focus on the sicker patients and decrease the burden on patients. This assessment tool could also allow patients to be more involved in self-management. Where mothers had received the combination of an anti-TNF agent and thiopurine, the relative infection risk compared with anti-TNF monotherapy was 2.7 (95% CI 1.09-6.78).
Comment: There are limited data on anti-TNF clearance and development of infection in infants exposed to anti-TNFs in utero. This international multicentre prospective study included 80 pregnant women with IBD from Denmark, Australia and New Zealand. Time from last exposure was inversely correlated to umbilical cord drug concentration. The median time to drug clearance was slower for infliximab at 7.3 months versus adalimumab at 4.0 months. There was no significant difference in disease flares in women who stopped anti-TNF therapy before or after gestational week 30. These data add to our growing understanding of anti-TNF kinetics. The increased risk of infection in infants exposed to combination therapy is consistent with the PIANO study and we should exercise caution using combination therapy in pregnant patients. This important study will assist in counselling and managing pregnant patients exposed to these drugs.
Reference: Gastroenterology; Published online Apr 7, 2016 Abstract
Live birth and adverse birth outcomes in women with ulcerative colitis and Crohn's disease receiving assisted reproduction Comment: Women with IBD are expected to have infertility rates at least as high as the general population (10-15%), particularly in the setting of pelvic surgery, and are therefore candidates for assisted reproductive therapy. This large nationwide cohort study allows us to do subgroup analyses on the outcomes of assisted reproductive therapy according to IBD type and prior surgery, but could not account for confounders including disease severity and/or medications. Both UC and CD patients have less success with assisted reproductive therapy. UC surgery does not affect fertility, possibly explained by removal of the colon and source of inflammation. This is reassuring, as patients with IPAA have higher infertility rates. The risk of higher preterm birth in women with UC, except those with singleton pregnancies, raises concern, and these patients need to be closely monitored during pregnancy. Women with CD can be reassured that they will have normal pregnancy outcomes with assisted reproductive therapy. This study did not address the effect of assisted reproductive therapy on the course of IBD.
Higher adalimumab drug levels are associated with mucosal healing in patients with Crohn's disease Authors: Zittan E et al. Summary: These authors reviewed data from 60 patients who had received adalimumab for CD. Compared with patients without mucosal healing, those with mucosal healing had a significantly lower median C-reactive protein level (1.2 vs. 14.4 mg/dL) and a significantly higher median adalimumab trough concentration (14.7 vs. 3.4 µg/mL). Median adalimumab trough concentration was also significantly higher in patients with clinical and endoscopic remission (13.0 vs. 4.8 µg/mL). A cutoff adalimumab trough concentration of 8.14 µg/mL was identified as best for discriminating between patients with versus without mucosal healing, with respective sensitivity and specificity values of 91.4% and 76.0% and respective positive and negative predictive values of 84.2% and 86.4%.
Comment: Most prior studies assessing anti-TNF drug concentrations have looked at infliximab. Those assessing adalimumab trough concentrations have mostly used clinical indices as the primary outcome measure. In this retrospective study, patients in the maintenance phase of adalimumab therapy with mucosal healing had higher adalimumab trough concentrations compared with those without. The optimum adalimumab trough concentration in this study, using the Prometheus assay, of 8.14 μg/mL is higher than previously reported. This threshold may vary depending on the assay used, timing of sampling and the study population (UC versus CD). In this study, serum was taken at various times, not truly trough, although it is thought that subcutaneously administered drugs have a more flat drug-concentration curve. This study further suggests that higher anti-TNF levels are associated with mucosal healing and may assist in a step towards personalised medicine. We need to await large, prospective trials.
Reference: J Crohns Colitis 2016;10(5):510-5 Abstract
Switching between infliximab originator and biosimilar in paediatric patients with inflammatory bowel disease: preliminary observations Authors: Sieczkowska J et al.
Summary: This paper reported on 32 paediatric patients with CD and seven with UC who were switched from the infliximab originator to a biosimilar, Remsima. The mean numbers of infliximab originator infusions prior to switching to the biosimilar in the CD and UC patients were 9.9 and 5.1, respectively. The clinical remission rates after biosimilar use were 88% and 57% in the CD and UC patients, respectively, and at latest follow-up 80% of patients with CD and four of those with UC were in remission. One of the patients with CD had an infusion reaction to the biosimilar, leading to discontinuation. Switching to the biosimilar did not significantly alter the incidence of sporadic mild adverse events, with the safety profile of the biosimilar consistent with that of infliximab.
Comment: Inflectra, a biosimilar for infliximab, is now available on the PBS and there are other biosimilars on the horizon. There is limited information on the long-term efficacy and safety of switching from one biological drug to a biosimilar, and there is concern that this may occur at a pharmacy level. Due to subtle differences in structure between the biosimilar and the originator, there is a risk of immunogenicity. This is a very small study showing that a switch appears to be safe, but certainly not sufficient to allay concerns. We require larger registry studies, and in the interim, pharmacovigilance is required.
Reference: J Crohns Colitis 2016;10(2):127-32 Abstract
Available anytime on your computer, tablet or smartphone
PARTICIPATE NOW!
Go to www.mdBriefCase.com.au Login or register (it's free and confidential) Select the A novel approach to the treatment of active mild to moderate ulcerative colitis program, listed under "Specialist Programs"
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